Press Releases Detail:
Avitar, Inc. Adds ORALscreen 2 to ORALscreen Product Line
New addition is company’s most cost-effective oral fluid-based rapid substance abuse test to date
November 27, 2000
CANTON, MA, November 27, 2000 – Avitar, Inc. (AMEX: AVR) today launched ORALscreen™ 2, the newest addition to the company’s product line of rapid point-of-collection screening test for drugs-of-abuse. The new 2-panel drug test identifies the presence of cocaine and marijuana. It is estimated that over 80 percent of all positive results for drugs-of-abuse are for THC and cocaine.
"Avitar quickly developed and produced ORALscreen 2 in response to its numerous requests from customers within the criminal justice market and related organizations that represent potential market revenues of over $150 million per year," said Peter P. Phildius, Avitar’s Chairman and Chief Executive Officer. "The advantage of our patented technology in oral fluid collection gives our customers, specifically the corrections, probation and parole community, a test that can be used by enforcement officers in the field giving them the means to quick and reliable results for these commonly-used drugs."
"Flexibility in product development is important in a budget-sensitive market, such as criminal justice, putting Avitar at a tremendous advantage when we can quickly customize a product to satisfy our customers’ needs," added Phildius.
Avitar’s ORALscreen product line is the world’s first oral fluid point-of-collection drugs-of-abuse system for detecting marijuana (THC), cocaine, opiates, methamphetamine, and MDMA also known as Ecstasy. ORALscreen is a highly sensitive, simple-to-use, reliable portable drug test that detects the presence of specific illegal substances within minutes. While urine testing requires the off-premises, humiliating collection of adulterable samples, with ORALscreen, oral fluid is collected under readily observable conditions, on-site and on-demand, making it nearly impossible to contaminate test results.
Avitar, Inc. (AMEX:AVR) headquartered in Canton, Massachusetts, develops, manufactures and markets innovative medical devices based on core technologies in oral fluid diagnostics and customized polyurethane applications. The Company markets a unique portfolio of substance abuse testing products and services that include ORALscreenTM, the world’s first rapid point-of-contact oral fluid test for drugs of abuse, ORALadvantageTM, the first comprehensive substance abuse program featuring its oral fluid-based products, HAIRscreenTM, a laboratory-based test for long term drug abuse using hair, and several other specialized tests for drugs of abuse. ORALscreen is a cost-effective drugs-of-abuse test with potential net cost savings of more than $100.00 per sample tested. Additional products include an oral fluid collection system for DNA testing as well as a proprietary line of polyurethane-based high tech medical devices.
For more information, see Avitar’s website at avitarinc.com.
This release forward looking statements that are subject to risks and uncertainties, including the development and marketing of new applications and other risks that are detailed from time to time in the Company’s filings with the Securities and Exchange Commission.